COVID - 19
June 24, 2020 | RR Baliga, MD, MBA
Question Is the receipt of colchicine among patients hospitalized with symptomatic coronavirus disease 2019 associated with clinical benefit? Findings In this randomized clinical trial of 105 patients, the rate of the primary clinical end point (clinical deterioration) was higher in the control group than in the colchicine group, and the time to clinical deterioration was shorter in the control group than in the colchicine arm. No difference was observed in the primary biochemical end point (high-sensitivity troponin concentration), but patients in the colchicine group had a smaller increase in dimerized plasma fragment D compared with patients in the control group. Meaning The hypothesis-generating findings of this study suggest a role for colchicine in the treatment of patients with coronavirus disease 2019.
May 27, 2020 | RR Baliga, MD, MBA
Masks reduce airborne transmission : Infectious aerosol particles can be released during breathing and speaking by asymptomatic infected individuals. No masking maximizes exposure, whereas universal masking results in the least exposure.
May 26, 2020 | RR Baliga, MD, MBA
BMJ: Martineau is pragmatic: “At best vitamin D deficiency will only be one of many factors involved in determining outcome of COVID-19, but it's a problem that could be corrected safely and cheaply
May 25, 2020 | RR Baliga, MD, MBA
In patients hospitalized with COVID-19 and not initially intubated, famotidine use was associated with a two-fold reduction in clinical deterioration leading to intubation or death. These findings are observational and should not be interpreted to mean that famotidine has a protective effect against COVID-19. Randomized controlled trials are underway
May 20, 2020 | RR Baliga, MD, MBA
Tamsulosin and Prazosin to prevent Cytokine Release Syndrome in COVID-19?
May 18, 2020 | RR Baliga, MD, MBA
R0, Rt, Herd-immunity, Infection fatality rate & Death Rates
May 15, 2020 | RR Baliga, MD, MBA
Kawasaki Syndrome and COVID-19 or PIMS-TS (Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-COV2 --30 fold increase in Kawasaki in children with Covid
March 24, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
COVID-19 World Health Organization (WHO) led 'SOLIDARITY' & FRENCH led 'DISCOVERY' TRIALS
March 21, 2020 | RR Baliga, MD, FRCP (Edin), FACP, FACC
Hydroxychloroquine and azithromycin as a treatment of COVID-19
March 20, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
COVID-19 in Patients with Heart Disease and Cancer
March 20, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
Convalescent Serum for Influenza Pneumonia JAMA 1918
March 19, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
COVID-19 Update March 19th 2020, 6 pm
March 18, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
Lopinavir–Ritonavir NOT Effective in Severe COVID19 | Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians, NEJM
March 18, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
Psychological Impact of Quarantine: How To Reduce it
March 16, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
Tocilizumab to Manage Cytokine Release Syndrome Associated with Severe COVID-19 infections
March 15, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
What is the impact of ACE-Inhibitors/ARBs in COVID19 patients?
March 15, 2020 | RR Baliga, MD, MBA
What is the impact of ACE-Inhibitors/ARBs in COVID19 patients?
March 15, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC
Clinical Course & Risk Factors for Mortality of Adult Patients with Covid-19
March 2, 2020 | RR Baliga, MD, MBA
Clinical Characteristics of Covid-19 infection